F_CSS_NonComp Posting.pdf

NON-COMPETITIVE

COMBINED SYNOPSIS / SOLICITATION

Title: 75 Compounds to Support Ongoing COVID-19 Research

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued.

(ii) The solicitation number is 75N95022Q00218 and the solicitation is issued as a request for quotation (RFQ).

This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures;

and FAR Part 12—Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold.

THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS

SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT

PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).

The National Institute on Drug Abuse (NIDA), NIDA Office of Acquisitions – National Center for Advancing Translational Sciences (NCATS) Section, on behalf of the NCATS intends to negotiate and award a purchase order without providing for full and open competition (Including brand-name) to MedChemExpress, LLC, 18 Wilkinson Way, Princeton, New Jersey, 08540-7346, for the purchase of 75 compounds for use in ongoing COVID-19 research. The anticipated award date is 5/16/2022.

This acquisition is non-competive due to the need for scientific continuity. The required compounds will be used as part of a long term SARS-CoV2 study, that has previously used these exact MedChemExpress compounds to perform research. To ensure continuity of science, we must continue to use these exact compounds since to introduce any other vendor's items, made using different processes and procedures, could compromise data integrity and invalidate results.

(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2022-06, dated 05/01/2022.

(iv) The associated NAICS code 325414 and the small business size standard is 1250 employees. This requirement has no set-aside restrictions.

(v) Project requirements:

Please see Attachment 1, List of Required Compounds.

(vi) Delivery Location:

The National Center for Advancing Translational Sciences (NCATS) 9800 Medical Center Drive Rockville, MD 20850

(vii) The provision at FAR clause 52.212-1, Instructions to Offerors – Commercial Products and Commercial Services, applies to this acquisition.

(viii) The provision at FAR clause 52.212-2, Evaluation – Commercial Products and Commercial Services, applies to this acquisition.

(a) The award resulting from this solicitation will be made to the responsible offeror whose proposal is most advantageous to the Government, Technical Capability, Past Peformance and other factors considered.

(ix) Offerors are to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications—Commercial Products and Commercial Services, with its offer.

(x) The FAR clause at 52.212-4, Contract Terms and Conditions – Commercial Products and Commercial Services, applies to this acquisition.

The following FAR provisions or clauses are incorporated by reference:

52.204-7, System for Award Management (Oct 2018) 52.204-13, System for Award Management Maintenance (Oct 2018) 52.204-16, Commercial and Entity Code Reporting (Aug 2020) 52.204-18, Commercial and Entity Code Maintenance (Aug 2020) 52.204-24, Representation Regarding Certain Telecommunications and Video Surveillance Services of Equipment (Nov 2021) HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015).

52.212-4(g), Invoice, is supplemented by the NIH Invoice and Payment Instructions (2/2014).

(xi) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders–Commercial Products and Commercial Services, applies to this acquisition

(xii) HHS reserves the right to exercise priorities and allocations authority with respect to this contract, to include rating this order in accordance with 45 CFR Part 101, Subpart A - Health Resources Priorities and Allocations System.

(xiii) The offeror must complete and return FAR 52.204-24 with its offer.

(xiv) Responses to this solicitation must include sufficient information to establish the interested parties’ bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance;

trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability; and environmental and energy efficiency considerations.

In addition the Unique Entity Identifier (UEI), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.”

All responses must be received by May 12, 2022, 9:00 am, Eastern Standard Time and reference number 75N95022Q00218. Responses shall be submitted electronically to Kevin Alvarez, Contracting Officer, kevin.alvarez@nih.gov.

Fax responses will not be accepted.

(xv) The name of the individual to contact for information regarding the solicitation:

Kevin Alvarez, Contracting Officer, kevin.alvarez@nih.gov.

Attachments:

1. List of Required Compounds

2. FAR 52.212-5

3. Copy of FAR 52.204-24, to be completed and submitted by offeror

4. Invoice and payment provisions http://www.sam.gov/ mailto:kevin.alvarez@nih.gov mailto:kevin.alvarez@nih.gov

Attachment 1: List of Required Compounds

Required Compounds – Solicitation 75N95022Q00218

100MG QUANTITY IS REQUESTED FOR ALL COMPOUNDS

Drug Name Catalog Number Rifamycin HY-B1907A Dacomitinib HY-13272 Binimetinib HY-15202 Fostamatinib HY-13038A Apalutamide HY-16060 Duvelisib HY-17044 Talazoparib HY-16106 Encorafenib HY-15605 Glasdegib HY-16391 Omadacycline HY-14865 Tezacaftor HY-15448 Lorlatinib HY-12215 Tecovirimat HY-14805 Nestoron HY-13071 Tafenoquine HY-111529 Larotrectinib HY-12866 Doravirine HY-16767 Avatrombopag HY-13463 Elagolix sodium HY-14369 Revefenacin HY-15851 Bictegravir HY-17605 Ferric maltol HY-108017 Triclabendazole HY-B0621 Fedratinib HY-10409 Roxadustat HY-13426 Pretomanid HY-10844 Alpelisib HY-15244 Siponimod HY-12355 Sotagliflozin HY-15516 Pexidartinib HY-16749 Entrectinib HY-12678 Darolutamide HY-16985 Lemborexant HY-16725 Voxelotor HY-18681 Bremelanotide HY-18678 Relebactam HY-16752 Lumateperone HY-19733 Upadacitinib HY-19569 Tenapanor HY-15991 Lactitol HY-N7104 Opicapone HY-14896

Attachment 1: List of Required Compounds

Lurbinectedin HY-16293 Maribavir HY-16305 Asciminib HY-104010 Avacopan HY-17627 Mobocertinib HY-135815 Difelikefalin HY-17609 Belzutifan HY-125840 Odevixibat HY-109120 Belumosudil HY-15307 Fexinidazole HY-13801 Infigratinib HY-13311 Sotorasib HY-114277 Ponesimod HY-10569 Melflufen HY-105019 Trilaciclib HY-101467 Umbralisib HY-12279 Voclosporin HY-106638 Vericiguat HY-16774 Abrocitinib HY-107429 Anamorelin HY-14734 Imeglimin HY-14771 Tucidinostat HY-109015 Difamilast HY-109085 Nirmatrelvir HY-138687 Molnupiravir HY-135853 Lenacapavir HY-111964 Mavacamten HY-109037 Deucravacitinib HY-117287 Adagrasib HY-130149 Sarecycline HY-16770 Maralixibat HY-121479 Atogepant HY-109022 Fosdenopterin HY-109145 Upacicalcet HY-109106

• Each compound must be provided at 100mg quantity.

• Each compound should be provided with a confirmed purity equal or higher than 95%(≥ 95).

• In case of nonavailability, lower compound purity MAY be accepted by NCATS. Compounds with less than 90% (<90) purity shall not be considered.

• Certificate of Analysis and Standard Operating Procedure must be supplied to NCATS.

• The compounds must be replenishable. They must be available for resupply or resynthesis if needed for NCATS follow up in the future. If this is needed, additional quantity will be ordered under a separate, future purchase order.

• Packing and Shipping must be included in price quote.